Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
AU2016244316A1
Production of glycoproteins
AU2016225895A1
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof
AU2016219711A1
Processes for the convergent synthesis of calicheamicin derivatives
AU2016208353A1
Immunotherapy regimes dependent on ApoE status
AU2016204760A1
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016202225A1
Antineoplastic combinations containing HKI-272 and vinorelbine
AU2016201221A1
Peripheral opioid receptor antagonists and uses thereof
AU2016200133A1
Oral formulations and lipophilic salts of methylnaltrexone
US2017119778A1
Triazine compounds as PI3 kinase and mTOR inhibitors
AU2015202418A1
Designer osteogenic proteins
US2016052984A1
Designer osteogenic proteins
AU2015376655A1
Improved osteogenic proteins
AU2014268186A1
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014206168A1
Production of glycoproteins
US2014322263A1
Pneumococcal dosing regimen
AU2014202414A1
Processes for the convergent synthesis of calicheamicin derivatives
AU2013263750A1
Formulations for parenteral delivery of compounds and uses thereof
